Literature DB >> 30964116

Efficacy and safety of a combination of hydrodissection and radiofrequency ablation therapy for benign thyroid nodules larger than 2 cm: A retrospective study.

Dan Cui1, Min Ding1, Xiaoyin Tang1, Jiachang Chi1, Yaoping Shi1, Tao Wang1, Bo Zhai1, Ping Li1.   

Abstract

BACKGROUND: Radiofrequency ablation (RFA) is a safe, highly effective, and novel method used to treat benign thyroid nodules. This study aimed to evaluate the efficacy and safety of a combination of RFA and hydrodissection for treating benign thyroid nodules larger than 2 cm.
MATERIALS AND METHODS: The data of 137 patients with at least one thyroid nodule ≥2 cm who underwent RFA combined with hydrodissection at our medical center from November 2014 to October 2016 were analyzed. Ultrasound-guided RFA was applied to 532 nodules, including 139 nodules ≥2 cm and 393 nodes <2 cm.
RESULTS: The volumes of thyroid nodules, complications, and changes in thyroid function were analyzed. Ablation treatments were successfully performed without intraoperative skin burns, serious bleeding, or serious thyroid storm. A positive correlation was observed between ablation time and nodule size (R2 = 0.674). Only one patient (0.7%) experienced laryngeal nerve injury after operation. Moreover, the results of thyroid function tests (free triiodothyronine, free thyroxine, and thyroid-stimulating hormone) remained within normal ranges both before and after ablation. The complete ablation rate was 99.06%. The volumes of both nodules ≥2 cm and <2 cm significantly decreased after ablation. Six months after ablation, the average volume of nodules ≥2 cm had decreased to 1.02 ± 2.42 mL, and the volume reduction ratio was 83.11%.
CONCLUSION: The combination of ultrasound-guided RFA with hydrodissection very effectively treats benign thyroid nodules while reducing damage to the surrounding tissues. This method is safe and effective for treating benign thyroid nodules.

Entities:  

Keywords:  Hydrodissection; radiofrequency ablation; safety and efficacy; thyroid nodule; ultrasonography

Mesh:

Substances:

Year:  2019        PMID: 30964116     DOI: 10.4103/jcrt.JCRT_419_18

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  7 in total

1.  Radiofrequency ablation and thyroid nodules: updated systematic review.

Authors:  Haris Muhammad; Prasanna Santhanam; Jonathon O Russell
Journal:  Endocrine       Date:  2021-01-15       Impact factor: 3.633

2.  Horner's Syndrome During High-Intensity Focused Ultrasound Ablation for a Benign Thyroid Nodule.

Authors:  Adrien Ben Hamou; Hervé Monpeyssen
Journal:  AACE Clin Case Rep       Date:  2021-01-07

3.  Radiofrequency ablation of functioning and non-functioning thyroid nodules: a single institution 12-month survey.

Authors:  C Cappelli; F Franco; I Pirola; E Gandossi; F Marini; E Di Lodovico; C Casella; D Lombardi; A Cristiano; A Ferlin; M Castellano
Journal:  J Endocrinol Invest       Date:  2019-10-25       Impact factor: 5.467

4.  Radiofrequency ablation of benign thyroid nodules: recommendations from the Asian Conference on Tumor Ablation Task Force.

Authors:  Eun Ju Ha; Jung Hwan Baek; Ying Che; Yi-Hong Chou; Nobuhiro Fukunari; Ji-Hoon Kim; Wei-Che Lin; Le Thi My; Dong Gyu Na; Lawrence Han Hwee Quek; Ming-Hsun Wu; Koichiro Yamakado; Jianhua Zhou
Journal:  Ultrasonography       Date:  2020-09-08

5.  A Novel Strategy for Single-Session Ultrasound-Guided Radiofrequency Ablation of Large Benign Thyroid Nodules: A Pilot Cohort Study.

Authors:  Zhicheng Yao; Tao Wu; Bowen Zheng; Lei Tan; Yufan Lian; Bo Liu; Jie Ren
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-07       Impact factor: 5.555

Review 6.  RFA and benign thyroid nodules: Review of the current literature.

Authors:  Haris Muhammad; Prasanna Santhanam; Jonathon O Russell; Jennifer H Kuo
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-01-09

7.  Safety and Efficacy of Radiofrequency Ablation of Thyroid Nodules-Expanding Treatment Options in the United States.

Authors:  Iram Hussain; Fizza Zulfiqar; Xilong Li; Shahzad Ahmad; Jules Aljammal
Journal:  J Endocr Soc       Date:  2021-06-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.